centrosomal protein 120Genealiases: CCDC100 · JBTS31 · SRTD13
Q-omics provides the consensus-scored CEP120 profile across patient tissues and cancer cell-line models. CEP120 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CEP120 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CEP120 RNA expression shows 21,436 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where CEP120 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP120 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP120 survival associations across molecular data types. CEP120 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP120 RNA expression–survival associations across cancer types. High CEP120 expression shows unfavorable associations in OV, THCA and LGG, but favorable associations in KIRC, SKCM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CEP120 RNA expression.
This table summarizes CEP120 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP120. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP120 shows lower tumor expression in LUSC, THCA and UCEC and higher tumor expression in KIRC, HNSC and CHOL. The KIRC box plot shows higher CEP120 RNA expression in tumor versus normal tissue (log2 FC = +0.521, t-test p < 0.001).
This table shows molecular features associated with CEP120 in patient tissues and cancer cell lines. In patient samples, CEP120 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP120 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
